Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...
Cetuximab combined with chemotherapy significantly improves PFS and OS in mCRC patients, as confirmed by a meta-analysis of 25 studies. The study highlights cetuximab's efficacy, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback